Healthcare / Medical DevicesNYSE American
$8.95
+0.07 (+0.73%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 25% · confianza 25%
FCF escenarios
weak_data · normalized FCF $2.6M · quality 54.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
59/100
C
Piotroski
8/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$181M
P/E
24.4x
↑EV/EBITDA
8.3x
↓ROE
11.6%
↑Gross Margin
56.0%
↑Debt/Equity
0.40
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2009–2025 · 16 años de histórico normalizado
Revenue CAGR
+8.5%
FCF CAGR
—
FCF margin
11.0%
FCF / Net income
2.37x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $143.4M · net income $6.6M · FCF $15.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||||||||||
| Revenue | $143.4M | $143.4M | $134.9M | $125.8M | $109.9M | $102.4M | $97.4M | $81.1M | $67.1M | $71.1M | $70.5M | $70.5M | $66.5M | $62.3M | $58.8M | $54.6M | $47.2M | $39.0M |
| Net Income | $6.6M | $6.6M | $2.3M | $872000.00 | $18000.00 | $1.4M | $17.3M | $1.4M | $-1.1M | $-20.7M | $-222000.00 | $2.8M | $3.4M | $1.7M | $-1.5M | $-45.4M | $-1.9M | $774000.00 |
| EBITDA | $25.2M | $25.2M | $19.3M | $16.5M | $14.9M | $17.4M | $22.9M | $15.9M | $11.7M | — | — | — | — | — | — | — | — | — |
| EPS | 0.31 | 0.31 | 0.11 | 0.04 | 0.00 | 0.06 | 0.80 | 0.07 | -0.05 | -0.91 | -0.01 | 0.12 | 0.15 | 0.08 | -0.07 | -2.16 | -0.09 | 0.04 |
| Gross Margin | 56.0% | 56.0% | 52.2% | 50.2% | 55.1% | 57.2% | 60.3% | 57.8% | 58.9% | 61.0% | 63.5% | 70.3% | 71.2% | 70.1% | 72.9% | 64.7% | 71.0% | 73.5% |
| Operating Margin | 8.3% | 8.3% | 5.1% | 3.2% | 1.5% | 2.8% | 9.1% | 4.3% | 0.6% | -5.4% | 1.4% | 10.3% | 14.0% | 9.5% | 3.4% | -121.4% | -2.0% | 13.7% |
| Net Margin | 4.6% | 4.6% | 1.7% | 0.7% | 0.0% | 1.4% | 17.8% | 1.7% | -1.6% | -29.1% | -0.3% | 3.9% | 5.0% | 2.7% | -2.5% | -83.2% | -3.9% | 2.0% |
| Balance Sheet | ||||||||||||||||||
| Debt/Equity | 0.40 | 0.40 | 0.49 | 0.67 | 0.77 | 0.68 | 0.72 | 1.36 | 1.41 | 0.82 | 0.52 | 0.53 | 0.41 | 0.51 | 0.68 | 0.56 | 0.31 | — |
| Current Ratio | 2.14 | 2.14 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | ||||||||||||||||||
| Free Cash Flow | $15.7M | $15.7M | $2.6M | $106000.00 | $2.4M | $17.3M | $19.2M | $10.9M | $11.1M | $7.6M | $7.7M | — | — | $2.7M | — | — | — | — |
| Returns | ||||||||||||||||||
| ROE | 11.6% | 11.6% | 4.1% | 1.7% | 0.0% | 2.9% | 42.5% | 6.1% | -5.4% | -66.9% | -0.4% | 5.5% | 7.2% | 3.9% | -3.7% | -113.1% | -2.2% | 1.0% |
| Valuation | ||||||||||||||||||
| P/E | 24.36 | 24.36 | 74.64 | 247.75 | 10946.11 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| EV/EBITDA | 8.33 | 8.33 | 10.66 | 15.08 | 15.69 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| P/B | 3.32 | 3.32 | 3.10 | 4.10 | 4.10 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | ||||||||||||||||||
| Revenue Growth | 6.4% | 6.4% | 7.2% | 14.4% | — | 5.1% | 20.1% | 20.8% | -5.5% | 0.8% | -0.1% | 6.1% | 6.8% | 5.9% | 7.7% | 15.7% | 21.2% | — |
| EPS Growth | 181.8% | 181.8% | 175.0% | 4690.4% | — | -92.5% | 1042.9% | 240.0% | 94.5% | -9000.0% | -108.3% | -20.0% | 87.5% | 214.3% | 96.8% | -2300.0% | -325.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
36.8%
EPS terminal req.
$0.79
Spread vs growth
145.0%
5Y implied EPS CAGR
25.4%
EPS terminal req.
$0.96
Spread vs growth
156.4%
10Y implied EPS CAGR
17.4%
EPS terminal req.
$1.55
Spread vs growth
164.4%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+58.7%
Start / end P/E
51.6x → 29.1x
EPS bridge
0.11 → 0.31
Residual
-79.4%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.